Overview

A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

This is a phase 2 study of the HSP90 inhibitor, STA-9090 (ganetespib) in subjects with stage IIIB or IV non-small cell lung cancer (NSCLC).

Phase:

Phase 2

Details

Lead Sponsor:

Synta Pharmaceuticals Corp.